Chad Walkaden is the CEO and founder of OnTracka, an Australian digital health company delivering compliant infrastructure for remote patient monitoring, real-world evidence generation, and hybrid clinical research across highly regulated therapeutic areas including oncology, obesity, endometriosis, and mental health.

Under his leadership, OnTracka has supported FDA-approved randomised clinical trials internationally, alongside TGA-aligned clinical research and real-world evidence programs in Australia. 

Chad also initiated the academic collaboration behind From Dose to Decision Making, supporting the development of practical frameworks for translating structured real-world data into regulatory-grade evidence. 

His work has enabled world-first longitudinal datasets in PTSD and psychedelic-assisted therapies, as well as the first structured dataset examining natural medicine use within Aboriginal and Torres Strait Islander communities. 

A stage four cancer survivor, Chad brings lived experience to building evidence-led digital health systems that clinicians, researchers, and regulators can trust.